Trial Profile
Symlin Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 16 Oct 2011 Planned End Date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 16 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2011 Planned end date changed from May 2011 to May 2012 as reported by ClinicalTrials.gov.